Morgan Stanley’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $168M | Buy |
317,548
+29,126
| +10% | +$13.4M | 0.01% | 1152 |
|
|
2026
Q1 | $138M | Sell |
288,422
-128,256
| -31% | -$65.7M | 0.01% | 1181 |
|
|
2025
Q4 | $234M | Sell |
416,678
-94,245
| -18% | -$53.5M | 0.01% | 857 |
|
|
2025
Q3 | $263M | Buy |
510,923
+22,696
| +5% | +$9.91M | 0.02% | 783 |
|
|
2025
Q2 | $153M | Buy |
488,227
+188,421
| +63% | +$56.6M | 0.01% | 1027 |
|
|
2025
Q1 | $91.3M | Buy |
299,806
+62,339
| +26% | +$21M | 0.01% | 1314 |
|
|
2024
Q4 | $78.9M | Buy |
237,467
+402
| +0.2% | +$136K | 0.01% | 1438 |
|
|
2024
Q3 | $79.1M | Sell |
237,065
-18,024
| -7% | -$6.85M | 0.01% | 1422 |
|
|
2024
Q2 | $105M | Sell |
255,089
-126,277
| -33% | -$50M | 0.01% | 1151 |
|
|
2024
Q1 | $154M | Buy |
381,366
+35,368
| +10% | +$12.4M | 0.01% | 922 |
|
|
2023
Q4 | $106M | Buy |
345,998
+35,125
| +11% | +$9.48M | 0.01% | 1114 |
|
|
2023
Q3 | $75.3M | Buy |
310,873
+23,687
| +8% | +$6.06M | 0.01% | 1253 |
|
|
2023
Q2 | $69M | Buy |
287,186
+18,038
| +7% | +$3.75M | 0.01% | 1319 |
|
|
2023
Q1 | $50.6M | Buy |
269,148
+76,580
| +40% | +$15.8M | 0.01% | 1529 |
|
|
2022
Q4 | $40.9M | Sell |
192,568
-57,580
| -23% | -$11.5M | ﹤0.01% | 1666 |
|
|
2022
Q3 | $39.3M | Buy |
250,148
+41,406
| +20% | +$6.61M | 0.01% | 1511 |
|
|
2022
Q2 | $31.2M | Buy |
208,742
+57,229
| +38% | +$8.28M | ﹤0.01% | 1803 |
|
|
2022
Q1 | $24.8M | Buy |
151,513
+82,247
| +119% | +$13.6M | ﹤0.01% | 1888 |
|
|
2021
Q4 | $15.1M | Sell |
69,266
-25,585
| -27% | -$5.36M | ﹤0.01% | 2478 |
|
|
2021
Q3 | $18M | Sell |
94,851
-5,641
| -6% | -$1.03M | ﹤0.01% | 2201 |
|
|
2021
Q2 | $17.8M | Sell |
100,492
-22,289
| -18% | -$3.85M | ﹤0.01% | 2287 |
|
|
2021
Q1 | $20.1M | Sell |
122,781
-19,366
| -14% | -$2.96M | ﹤0.01% | 1904 |
|
|
2020
Q4 | $19.8M | Buy |
142,147
+70,952
| +100% | +$8.94M | ﹤0.01% | 1824 |
|
|
2020
Q3 | $7.96M | Sell |
71,195
-46,217
| -39% | -$5.34M | ﹤0.01% | 2241 |
|
|
2020
Q2 | $10.9M | Sell |
117,412
-26,739
| -19% | -$2.28M | ﹤0.01% | 1890 |
|
|
2020
Q1 | $10.6M | Sell |
144,151
-65,913
| -31% | -$5.72M | ﹤0.01% | 1722 |
|
|
2019
Q4 | $17.7M | Buy |
210,064
+26,707
| +15% | +$2.07M | ﹤0.01% | 1778 |
|
|
2019
Q3 | $15.4M | Sell |
183,357
-21,714
| -11% | -$1.64M | ﹤0.01% | 1707 |
|
|
2019
Q2 | $13.4M | Buy |
205,071
+155,996
| +318% | +$8.99M | ﹤0.01% | 1853 |
|
|
2019
Q1 | $2.89M | Sell |
49,075
-54,992
| -53% | -$3.28M | ﹤0.01% | 3256 |
|
|
2018
Q4 | $5.51M | Sell |
104,067
-168,193
| -62% | -$9.23M | ﹤0.01% | 2791 |
|
|
2018
Q3 | $16.3M | Buy |
272,260
+200,839
| +281% | +$11M | ﹤0.01% | 1882 |
|
|
2018
Q2 | $3.07M | Buy |
71,421
+13,106
| +22% | +$529K | ﹤0.01% | 3676 |
|
|
2018
Q1 | $2.04M | Buy |
58,315
+5,251
| +10% | +$192K | ﹤0.01% | 4000 |
|
|
2017
Q4 | $1.92M | Buy |
53,064
+19,442
| +58% | +$681K | ﹤0.01% | 4066 |
|
|
2017
Q3 | $1.07M | Buy |
33,622
+23,849
| +244% | +$729K | ﹤0.01% | 4374 |
|
|
2017
Q2 | $284K | Sell |
9,773
-3,026
| -24% | -$84.9K | ﹤0.01% | 5141 |
|
|
2017
Q1 | $382K | Sell |
12,799
-58,683
| -82% | -$1.89M | ﹤0.01% | 4995 |
|
|
2016
Q4 | $2.58M | Buy |
71,482
+45,149
| +171% | +$1.5M | ﹤0.01% | 3691 |
|
|
2016
Q3 | $787K | Buy |
+26,333
| New | +$769K | ﹤0.01% | 4214 |
|
Other funds holding MEDP
WA
Morgan Stanley's MEDP Position: Q2 2026 in Review
Morgan Stanley increased its Medpace (MEDP) stake by 10% in Q2 2026, buying an estimated $13.4M and bringing the position to 317,548 shares worth $168M. The position accounts for 0.01% of the portfolio, ranked #1152.
Morgan Stanley first reported a position in MEDP in Q3 2016 and has held it in 40 quarters since. The position peaked at $263M in Q3 2025. 694 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.
- Morgan Stanley held 317,548 shares of Medpace worth $168M as of Q2 2026.
- Morgan Stanley bought 29,126 Medpace shares in Q2 2026, an estimated $13.4M.
- Medpace made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1152 holding.
- Morgan Stanley first reported a position in Medpace in Q3 2016 and has held it in 40 quarters since.
- Morgan Stanley's Medpace position peaked at $263M in Q3 2025.
- 694 funds tracked by Wall St. Rank held Medpace as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.